Clinical trial · no report yet · Phase 3
MagnetisMM-7
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
- NCT05317416 ↗
- Active, not recruiting
- Pfizer
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 3 | |
| Podcasts | 1 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab; Lenalidomide; Lenalidomide; Elranatamab
- Arms
- Arm A - Part 1 · Experimental
- Arm B - Part 1 · Active comparator
- Arm B - Part 2 · Active comparator
- Arm C - Part 2 · Experimental
- Enrollment
- 854
- Primary outcomes
- Progression Free Survival
- Sponsor
- Pfizer
- Start
- Mar 25, 2022
- Primary completion
- Aug 4, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05317416 · updated Apr 16, 2026